Literature DB >> 15937907

Therapy strategies for locally advanced adenoid cystic carcinomas using modern radiation therapy techniques.

Daniela Schulz-Ertner1, Anna Nikoghosyan, Bernd Didinger, Marc Münter, Oliver Jäkel, Christian P Karger, Juergen Debus.   

Abstract

BACKGROUND: The authors evaluated whether modern photon techniques, such as stereotactic fractionated radiation therapy (FSRT) or intensity-modulated RT, outweighed the biologic advantages of high-linear-energy transfer RT in the treatment of patients with locally advanced adenoid cystic carcinomas (ACC) that infiltrated the skull base or the orbit.
METHODS: Between June 1995 and December 2003, 63 patients with ACC were treated with modern RT techniques at the University of Heidelberg. The treatment results achieved with modern photon techniques alone were compared with the results achieved with combined photon RT and a carbon ion boost. Twenty-nine patients (Group A) were treated with a combination of photon RT and a carbon ion boost. Thirty-four patients (Group B) received photon RT alone.
RESULTS: The median follow-up was 16 months for Group A and 24 months for Group B. Locoregional control rates at 2 years and 4 years were 77.5% and 77.5% for Group A and 72.2% and 24.6% for Group B, respectively (P = 0.08; log-rank test). Disease-free and overall survival rates at 2 years/4 years were 71.5%/53% and 86.6%/75.8% for Group A and 69.2%/23% and 77.9%/77.9% for Group B, respectively. Rates for severe late toxicity were < 5% for both groups.
CONCLUSIONS: Modern RT techniques allowed the safe delivery of high target doses to patients with locally advanced ACC. Late toxicity rates were kept lower compared with the historic neutron therapy data. A combination of modern photon RT and carbon ion RT seemed to be advantageous, with a trend toward higher locoregional control rates compared with modern photon RT alone.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15937907     DOI: 10.1002/cncr.21158

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  39 in total

Review 1.  [Advances in radio-oncology. From precision radiotherapy with photons to ion therapy with protons and carbon ions].

Authors:  S E Combs; D Schulz-Ertner; K K Herfarth; R Krempien; J Debus
Journal:  Chirurg       Date:  2006-12       Impact factor: 0.955

Review 2.  [What is the impact of new radiotherapy techniques?].

Authors:  F Sterzing; M W Münter; A D Jensen; E M Stoiber; P Huber; K K Herfarth; J Debus
Journal:  HNO       Date:  2008-06       Impact factor: 1.284

Review 3.  Review of clinical experience with ion beam radiotherapy.

Authors:  A D Jensen; M W Münter; J Debus
Journal:  Br J Radiol       Date:  2011-03-22       Impact factor: 3.039

Review 4.  Adenoid cystic carcinoma: focus on heavy ion therapy and molecular imaging.

Authors:  Angelo Castello; Laura Olivari; Egesta Lopci
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-02-05

5.  Raster-scanned carbon ion therapy for malignant salivary gland tumors: acute toxicity and initial treatment response.

Authors:  Alexandra D Jensen; Anna V Nikoghosyan; Swantje Ecker; Malte Ellerbrock; Jürgen Debus; Klaus K Herfarth; Marc W Münter
Journal:  Radiat Oncol       Date:  2011-11-02       Impact factor: 3.481

6.  Carbon ion beam treatment in patients with primary and recurrent sacrococcygeal chordoma.

Authors:  Matthias Uhl; Thomas Welzel; Alexandra Jensen; Malte Ellerbrock; Thomas Haberer; Oliver Jäkel; Klaus Herfarth; Jürgen Debus
Journal:  Strahlenther Onkol       Date:  2015-03-04       Impact factor: 3.621

Review 7.  Controversies concerning the application of brachytherapy in central nervous system tumors.

Authors:  Bo-Lin Liu; Jin-Xiang Cheng; Xiang Zhang; Wei Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2010-02       Impact factor: 4.553

8.  Randomized phase II study evaluating a carbon ion boost applied after combined radiochemotherapy with temozolomide versus a proton boost after radiochemotherapy with temozolomide in patients with primary glioblastoma: the CLEOPATRA trial.

Authors:  Stephanie E Combs; Meinhard Kieser; Stefan Rieken; Daniel Habermehl; Oliver Jäkel; Thomas Haberer; Anna Nikoghosyan; Renate Haselmann; Andreas Unterberg; Wolfgang Wick; Jürgen Debus
Journal:  BMC Cancer       Date:  2010-09-06       Impact factor: 4.430

9.  Combined treatment of malignant salivary gland tumours with intensity-modulated radiation therapy (IMRT) and carbon ions: COSMIC.

Authors:  Alexandra D Jensen; Anna Nikoghosyan; Christine Windemuth-Kieselbach; Jürgen Debus; Marc W Münter
Journal:  BMC Cancer       Date:  2010-10-11       Impact factor: 4.430

Review 10.  Charged particle therapy--optimization, challenges and future directions.

Authors:  Jay S Loeffler; Marco Durante
Journal:  Nat Rev Clin Oncol       Date:  2013-05-21       Impact factor: 66.675

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.